The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
|Videos|August 16, 2022
The Importance of Imaging and Centralized Review in Clinical Trials
Author(s)MERIT
Imaging is an integral part of many clinical studies, particularly in the fields of oncology and ophthalmology. Learn why imaging and centralized review are essential for clinical trials, how to address challenges that arise in these studies, and the advantages of partnering with MERIT in this video.
Advertisement
- Imaging provides an unbiased, structural assessment of many disease states, which is a complement to functional outcome measures
- Centralized imaging review is particularly important in Phase II and III trials where multiple imaging sites are involved
- Centralized imaging challenges can be mitigated with 1) imaging expertise, 2) standardization through certified QMS, and 3) an integrated technology platform
Advertisement
Related to this article
Gilead agrees to acquire an oral IL-23R inhibitor from PepStar, while Zymeworks licenses its DLL3-targeting T cell engager ZW209 to Roche.
Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.
FDA has granted accelerated approval to Ultomiris based on Phase III data showing a 43.4% placebo-adjusted reduction at 34 weeks.
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
2
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
3
Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
4
Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma
5